152 related articles for article (PubMed ID: 20051952)
1. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Lee JM; Sarosy GA; Annunziata CM; Azad N; Minasian L; Kotz H; Squires J; Houston N; Kohn EC
Br J Cancer; 2010 Feb; 102(3):495-9. PubMed ID: 20051952
[TBL] [Abstract][Full Text] [Related]
2. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
3. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
[TBL] [Abstract][Full Text] [Related]
4. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Jain L; Sissung TM; Danesi R; Kohn EC; Dahut WL; Kummar S; Venzon D; Liewehr D; English BC; Baum CE; Yarchoan R; Giaccone G; Venitz J; Price DK; Figg WD
J Exp Clin Cancer Res; 2010 Jul; 29(1):95. PubMed ID: 20630084
[TBL] [Abstract][Full Text] [Related]
5. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Schultheis B; Neumann H; Roy R; Heuer V; Kummer G; Strumberg D
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):72-3. PubMed ID: 22192652
[No Abstract] [Full Text] [Related]
7. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Bodnar L; Górnas M; Szczylik C
Gynecol Oncol; 2011 Oct; 123(1):33-6. PubMed ID: 21723597
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Welch SA; Hirte HW; Elit L; Schilder RJ; Wang L; Macalpine K; Wright JJ; Oza AM
Int J Gynecol Cancer; 2010 Jul; 20(5):787-93. PubMed ID: 20847613
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R
Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098
[TBL] [Abstract][Full Text] [Related]
14. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Eisen T; Marais R; Affolter A; Lorigan P; Robert C; Corrie P; Ottensmeier C; Chevreau C; Chao D; Nathan PD; Jouary T; Harries M; Negrier S; Montegriffo E; Ahmad T; Gibbens I; James MG; Strauss UP; Prendergast S; Gore ME
Br J Cancer; 2011 Jul; 105(3):353-9. PubMed ID: 21750549
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
17. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
18. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Kupsch P; Henning BF; Passarge K; Richly H; Wiesemann K; Hilger RA; Scheulen ME; Christensen O; Brendel E; Schwartz B; Hofstra E; Voigtmann R; Seeber S; Strumberg D
Clin Colorectal Cancer; 2005 Sep; 5(3):188-96. PubMed ID: 16197622
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Hubbard JM; Kim G; Borad MJ; Johnson E; Qin R; Lensing J; Puttabasavaiah S; Wright J; Erlichman C; Grothey A
Invest New Drugs; 2016 Feb; 34(1):96-103. PubMed ID: 26581401
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
